Preclinical studies with multiple PCa in vitro cell lines and in vivo mouse model demonstrate that targeting the lnc-OPHN1-5/AR/hnRNPA1 complex with shhnRNPA1 leads to increase Enz treatment sensitivity to better suppress PCa progression. This evidence concerns the gene OPHN1 and posterior cortical atrophy.